This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These issues primarily stem from patients and healthcare providers miscalculating or incorrectly administering the drug. Compounded semaglutide products, unlike the US Food and Drug Administration (FDA)-approved ones, can vary widely in strength and packaging, making it easy for mistakes to happen.
CPhI Worldwide will see Gerresheimer showcase its latest developments in primary packaging, drugdeliverysystems for newly developed biologics along with medical and diagnostic products.
Robotics, for example, has facilitated the automation of medicine preparation and distribution, controlled drugdeliverysystems, and machine-readable coding on medicine packages. Newly emerging technologies have helped in improving the effectiveness and safety of non-sterile commercial dose products.
SHL Medical is a world-leading solutions provider for advanced drugdeliverysystems with a unified purpose to further enable patient independence. Consequently, pharmaceutical and biotech companies are increasingly looking to provide devices that allow patients to self-administer drugs.
The company developing drug product through such an intense process, use to consider container closure system only for packaging of the product. [1] In fact, a compromised container closure system can act as a vehicle for microbial transmission and pose a significant risk to patient safety. Our Social Media Platform.
The US Food and Drug Administration (FDA) also has concerns about the toxic effects of EtO and thus is continuing to encourage new ways to sterilize medical devices and strategies to mitigate the emission levels of EtO while achieving adequate sterilization.
Driven by the increasing need for safe and efficient medical devices and drugdeliverysystems, the pharmaceutical polymers / medical grade polymers domain is advancing significantly. There has been a rise in the development of polymers for biopharma with improved biocompatibility, biodegradability and functionality.
They offer several advantages over traditional drugdeliverysystems ( such as vials and syringes ), including reduced chances of dosing errors, increased patient compliance and decreased risk of microbial contamination.
When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. An example is the ability of a patient suffering from venous thrombosis to perform their own injections of heparin – an anticoagulant often packaged in a prefilled syringe.
XTALKS WEBINAR: DrugDelivery — Addressing Global Regulatory Challenges in Co-Packaged, On-Body Systems Live and On-Demand: Thursday, June 15, 2023, at 10am EDT (4pm CEST/EU-Central) Register for this free webinar to learn about on-body drugdeliverysystems and addressing their complex global regulatory requirements.
Deep S Bhattacharya, Senior Scientist, Drug Product Development and Design, Pfizer. Engage in panel discussions with industry leaders to navigate the accelerating digital health landscape for combination products and drugdeliverysystems. Who should Attend: Drug-delivery developers. Secondary packagers.
Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drugdelivery and drug-device combination product assembly in Rockford, Illinois.
In 2021, 72% of newly approved drugs were small molecules, and almost 50% of new drugs approved were OSD. While the industry is seeing advances in alternative drugdeliverysystems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry.
The demand for injectable drugs is rising. According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. Several drug development trends are driving injectables demand.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content